SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zvi Steinberg who wrote (1147)8/19/1998 11:47:00 AM
From: Zvi Steinberg  Read Replies (3) of 1491
 
Pharmos management were in Memphis, TN, at the Adams Mark Hotel Tuesday, August 18th. There were about 70 people in attendance for a very good meeting. Here are the highlights:

1. Unblinding of hu211 is on track for 1st week of October. If data is known in early Sept. the co. would issue a press release of the results then instead of waiting till the neuro conference in Oct.
2. Co. believes that the full phase 2 study must be completed and known before a partner would surface but anything is possible.
3. Pharmos doesn't think they'll have to raise any more money as they have enough thru the 1 qtr. 99. Much will be determined by how well Lotemax and Alrex do by year end.
4. The co mktg partner for Alrex is known by both B&L and Pharmos. B&L has been very slow to respond to Pharmos. It's been 4 weeks since Pharmos sent to B&L the last proposal for the co mktg partner. Actually, several of the sales reps of the co mktg partner have already gotten up to speed on the drug.
5. The 3rd eye drug, Lotemax-T should be a no brainer for approval and look for approval in late 99. Market for this drug would be larger than both Lotemax and Alrex.
6. There have been over 1100 prescrips written for Lotemax and Alrex already and is increasing daily
7. Co. has been very close to having well known firms pick up coverage but the analyst have been afraid to stick their neck out yet without hu211 data.
8. There are no co.s developing a neuro drug for head trauma and Pharmos feels that they have a winner in hu211.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News